Community Practice Connections™: Exploring Treatments on the Horizon in MGD-Associated Dry Eye Disease

CME: 1.0

Target Audience

This online activity targets practitioners who are involved in treating patients with MGD-associated DED, such as ophthalmologists, optometrists, NPs, PAs, and nurses.

Activity Overview

Dry eye disease (DED), one of the most common ocular diseases encountered by eye care professionals, is frequently the result of meibomian gland dysfunction (MGD). Historically, treatments for MGD have focused on alleviating symptoms using artificial tears or warming procedures with compression to melt and expel viscous meibum. Pharmacologic therapies include antibiotics and immunomodulators directed at inflammation, but no agents have yet been approved by the United States Food and Drug Administration specifically for MGD. Emerging agents may bring new mechanisms for MGD management.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a symposium presented at SECO 2022, held in March. This unique and engaging multimedia activity is ideal for the community-based clinician, with a focus on the practical aspects of managing patients with MGD-associated DED. The program also puts recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the impact that MGD-associated DED has on patients’ quality of life
  • Assess the efficacy and safety of currently available agents used for the treatment of MGD-associated DED
  • Identify the mechanisms of action of agents under investigation for the treatment of MGD-associated DED
  • Evaluate clinical trial data for investigational agents in the treatment of MGD-associated DED

Post a comment to this article